BioStock: Curasight targets neuroendocrine tumours

Danish Curasight recently announced the expansion of its clinical portfolio, pursuing the diagnostics and treatment of neuroendocrine tumours (NETs), a rare form of cancer with limited treatment options for late-stage patients. BioStock has taken a closer look at the current NET treatment landscape to shed some light on the possibilities this areas holds.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/04/curasight-targets-neuroendocrine-tumours/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se